Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 26, 2006

EpiCept Licenses Back Pain-Related Patent to Durect

  • Durect received exclusive, worldwide rights to certain of EpiCept's intellectual property for a transdermal patch containing bupivacaine for the treatment of back pain, under a license agreement. EpiCept will thus receive a $1-million upfront payment and up to an additional $9 million in milestone and royalty payments.

    "The signing of this license agreement directly supports our strategy to broaden the application of EpiCept's patent estate in managing back pain beyond the use of lidocaine," remarks Jack Talley, EpiCept president and CEO. “This arrangement with Durect advances our strategy to maximize the number of opportunities from which we may earn future royalties on the use of our patents.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »